Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (131-140 of 242) with videos related to

Pageof 25
Sort By:
Oncology Letters|August 16, 2013
Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: A case reportGouji Toyokawa, Kenichi Taguchi, Miyako Kojo, et al.
Trials|April 2, 2020
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET studyMototsugu Shimokawa, Kaname Nosaki, Takashi Seto, et al.
The Annals of Thoracic Surgery|September 4, 2013
Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancerMasafumi Yamaguchi, Gouji Toyokawa, Taro Ohba, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesotheliomaMasayuki Takeda, Yuichiro Ohe, Hidehito Horinouchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancerKatsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, et al.
International Journal of Clinical Oncology|August 29, 2022
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA studyShunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, et al.
Drug Safety|October 19, 2017
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety ResultsTerufumi Kato, Takashi Seto, Makoto Nishio, et al.
Lung Cancer (Amsterdam, Netherlands)|February 16, 2010
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502Takashi Seto, Takeharu Yamanaka, Izumi Wasada, et al.
Thoracic Cancer|July 23, 2022
Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 studyMinoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki, et al.
Cancer Science|August 28, 2016
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapyToyoaki Hida, Kazuhiko Nakagawa, Takashi Seto, et al.
Pageof 25

Showing results (131-140 of 242) with videos related to

Sort By:
Pageof 25
Oncology Letters|August 16, 2013
Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: A case reportGouji Toyokawa, Kenichi Taguchi, Miyako Kojo, et al.
Trials|April 2, 2020
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET studyMototsugu Shimokawa, Kaname Nosaki, Takashi Seto, et al.
The Annals of Thoracic Surgery|September 4, 2013
Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancerMasafumi Yamaguchi, Gouji Toyokawa, Taro Ohba, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesotheliomaMasayuki Takeda, Yuichiro Ohe, Hidehito Horinouchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancerKatsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, et al.
International Journal of Clinical Oncology|August 29, 2022
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA studyShunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, et al.
Drug Safety|October 19, 2017
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety ResultsTerufumi Kato, Takashi Seto, Makoto Nishio, et al.
Lung Cancer (Amsterdam, Netherlands)|February 16, 2010
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502Takashi Seto, Takeharu Yamanaka, Izumi Wasada, et al.
Thoracic Cancer|July 23, 2022
Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 studyMinoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki, et al.
Cancer Science|August 28, 2016
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapyToyoaki Hida, Kazuhiko Nakagawa, Takashi Seto, et al.
Pageof 25